Haemonetics Q4 FY2026 slides: earnings beat caps transformation plan

Haemonetics beat Q4 fiscal 2026 expectations with revenue of $346.4M versus $337.0M consensus and adjusted EPS of $1.29 versus $1.27, while completing its four-year transformation plan. Organic revenue rose 4.5% overall, or 8.6% excluding CSL-related impacts, though adjusted gross margin fell 50 bps to 59.7% and Plasma operating margin dropped 650 bps to 33.5%. The company issued fiscal 2027 guidance for 4% to 7% reported revenue growth, 50 to 100 bps of margin expansion, and about 80% free cash flow conversion; shares jumped 9.51% premarket.

Analysis

HAE looks like a classic post-transformation rerating setup: the market is no longer paying for execution credibility alone, but for the probability that the company can sustain mid-single-digit growth while converting a structurally higher share of earnings into cash. The important second-order effect is that a completed cost/revenue reset usually compresses the path to multiple expansion because investors stop discounting “what if the plan misses?” and start underwriting capital return plus incremental product wins. That said, the next leg of the stock is less about headline beats and more about whether the plasma mix can offset pressure from the lower-growth blood center franchise without forcing margin-sacrificing spend.

The biggest hidden winner may be the vascular closure and plasma ecosystem around HAE, not just the company itself. Regulatory clearance and label expansion increase the odds of share gains in adjacent procedures, which can force smaller niche competitors to defend with pricing or commercial spend; that tends to show up with a lag in their margins rather than immediately in market share data. The more interesting spillover is on suppliers and contract manufacturers tied to disposable kit volumes: if HAE’s launch cadence works, volume leverage should improve into FY27 even if reported growth looks only mid-single-digit because mix should shift toward higher-value platforms.

The main risk is that investors are extrapolating a clean guide while overlooking how much of the current profile depends on a few large end-markets and execution on new launches. A 50-100 bp margin expansion target is modest enough to be achievable, but if plasma mix or tariff pressure worsens, the market will likely punish the stock quickly because the current move has already pulled forward some of the rerating. Near term, the stock can continue to squeeze higher for days to weeks on momentum and buyback support; over 3-6 months, the test is whether organic growth holds above the guide’s low end and whether the market believes FY27 is a bridge to further expansion rather than a peak.

Consensus is probably underappreciating how much of the transformation benefit is already in the rear-view mirror and how much incremental upside now depends on capital allocation, not just operations. The stock may still be under-owned by generalists because it sits in the awkward zone between med-tech quality and industrial-style execution, which can create a lag before factor models reclassify it as a cash compounder. If management avoids margin slippage in Plasma and uses buybacks opportunistically, the rerating can extend; if not, this becomes a “good story, fair price” name quickly.

Key Decisions for Investors

• Long HAE on any intraday/1-3 day pullback after the gap-up; target a 6-10% upside over 1-2 months if the market starts valuing FY27 as a durable cash-compounding phase rather than a one-time reset.
• Sell upside calls / run a covered-call overlay in HAE for the next 30-45 days; implied volatility should remain elevated after the earnings gap, and the stock now has a higher probability of range trading unless the company prints another launch or margin catalyst.
• Pair trade: long HAE / short a lower-quality med-tech peer with weaker cash conversion and no near-term product catalyst over 2-4 months; HAE’s cash flow and buyback support should outperform if healthcare multiples remain selective.
• Monitor HAE against the 50-100 bp margin expansion guide: if the stock trades up on launch headlines but the next quarter shows plasma margin erosion, reduce exposure immediately; the risk/reward deteriorates fast if the market starts to doubt FY27 guide credibility.
• Add only on confirmation, not on momentum alone: wait for evidence that new product launches translate into sustained organic growth in the next 1-2 quarters before pressing size, since the move is already partially de-risked.